GMAB
Genmab A/S
There isn't enough reported data to score GMAB yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
GMAB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
GMAB's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GMAB PE Valuation
GMAB has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GMAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for GMAB, but weaker profitability. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over GMAB on the outlook, with more favorable profitability expectations.
GMAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $12.16 | +85% |
| Q2 2024 | $6.59 | -12% |
| Q1 2024 | $6.85 | -9.9% |
| Q4 2023 | $6.59 | -14% |
| Q2 2023 | $7.48 | +81% |
| Q1 2023 | $7.60 | +101% |
| Q4 2022 | $7.66 | +95% |
| Q2 2022 | $4.14 | +48% |
GMAB has the stronger earnings trend. Trailing diluted EPS is up 63% for GMAB versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
GMAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $2.1B | +17% |
| Q4 2024 | $1.8B | +27% |
| Q2 2024 | $115.8M | -81% |
| Q1 2024 | $89.6M | -79% |
| Q4 2023 | $1.4B | +1.2% |
| Q2 2023 | $619.6M | +32% |
| Q1 2023 | $421.2M | +34% |
| Q4 2022 | $1.4B | +89% |
GMAB has the stronger quarterly revenue trend. Revenue is up 49% for GMAB versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 25% | -11 points |
| Q4 2024 | 36% | +0.4 points |
| Q2 2024 | 30% | +16 points |
| Q1 2024 | 19% | -30 points |
| Q4 2023 | 36% | -3.5 points |
| Q2 2023 | 35% | +11 points |
| Q1 2023 | 15% | -20 points |
| Q4 2022 | 49% | +9.4 points |
GMAB's operating margin was 25% last quarter, down 11 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
GMAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $822M | +20% |
| Q4 2024 | $685.5M | +30% |
| Q2 2024 | $32M | -37% |
| Q1 2024 | $32M | -93% |
| Q4 2023 | $526.7M | +63% |
| Q2 2023 | $50.4M | -62% |
| Q1 2023 | $465.3M | +491% |
| Q4 2022 | $323.1M | +300% |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with GMAB at up 218%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
GMAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -7.7M shares |
| 1 year | -1.7% | -10.9M shares |
| 3 years | +4.5% | +27.9M shares |
| 5 years | +4.8% | +30M shares |
GMAB has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | — |
| Q2 2024 | $65.1M |
| Q1 2024 | $11.7M |
| Q4 2023 | — |
| Q2 2023 | $5.2M |
| Q1 2023 | $92.4M |
| Q4 2022 | $94.8M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GMAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2019 | -0.4x | Net Cash |
| Q1 2019 | -0.9x | Net Cash |
| Q4 2018 | -0.4x | Net Cash |
| Q3 2018 | -0.6x | Net Cash |
| Q2 2018 | -0.9x | Net Cash |
| Q1 2018 | -0.6x | Net Cash |
| Q4 2017 | -1.0x | Net Cash |
| Q3 2017 | -0.8x | Net Cash |
GMAB has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GMAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 75.6 | Overbought |
| Stochastic | 81.0 | Overbought |
GMAB's weekly RSI is 76 (overbought) and its Stochastic is 81 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GMAB PE vs Healthcare Sector
| Metric | GMAB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GMAB has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GMAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.8 | 18% above |
| 20 week MA | $36.3 | 43% above |
| 50 week MA | $31.8 | 63% above |
| 100 week MA | $27.7 | 87% above |
| 200 week MA | $29.7 | 74% above |
GMAB has climbed back above all five of its weekly moving averages, and it's now 74% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
GMAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.3 | $39.1 | +76% |
| 2021 | $39.1 | $39.7 | +1.5% |
| 2022 | $39.7 | $43.1 | +8.5% |
| 2023 | $43.1 | $31.8 | -26% |
| 2024 | $31.8 | $21.0 | -34% |
| 2025 | $21.0 | $33.4 | +59% |
| 2026 YTD | $33.4 | $51.7 | +55% |
GMAB has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.